Status:
UNKNOWN
A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol (S-HCC)
Lead Sponsor:
Taipei Veterans General Hospital, Taiwan
Conditions:
Gastroesophageal Varices Hemorrhage
Hepatocellular Carcinoma
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
Patients with hepatocellular carcinoma and esophageal varices bleeding were randomized to undergo endoscopic ligation alone (group A) and additive propranolol treatment (group B) after stabilization o...
Detailed Description
Esophageal variceal bleeding is characteristic of high rebleeding rate and mortality. Thanks to the recent advance of treatment for variceal bleeding such as non-selective beta blocker (NSBB) added to...
Eligibility Criteria
Inclusion
- clinical diagnosis of HCC
- endoscopically proven acute variceal bleeding
- younger than 18 years old or older than 80 years old
Exclusion
- Had a terminal illness of any major organ system,such as heart failure, kidney failure,COPD
Key Trial Info
Start Date :
December 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2020
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT01451658
Start Date
December 1 2009
End Date
December 31 2020
Last Update
September 4 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Veteran General Hospital-Taipei
Taipei, Ming-Chih Hou, MD, Taiwan, 11217